5-Methylmethiopropamine

Summary

5-Methylmethiopropamine (5-MMPA), or mephedrene, is a stimulant drug. Unlike mephedrone, it is not a substituted cathinone derivative because it lacks a ketone group at the β position of the aliphatic side chain. Instead, it bears a closer resemblance to substituted amphetamines. This compound was discovered in Germany in June 2020 and has since been marketed as a designer drug.

Identifiers
IUPAC name
CAS Number1340105-79-4 
PubChem CID64487873
ChemSpider46249721
UNIIZP92FK3KK5
Chemical and physical data
FormulaC9H15NS
Molar mass169.29 g·mol−1

FAQ

  • What is 5-Methylmethiopropamine (5-MMPA)?
  • 5-Methylmethiopropamine, often 5-MMPA or mephedrene, is a stimulant drug. It is structurally related to methiopropamine and shares similarities with substituted amphetamines.
  • How does 5-MMPA differ from mephedrone?
  • 5-MMPA is distinct from mephedrone in its chemical structure. Unlike mephedrone, it does not belong to the substituted cathinone class, mainly because it lacks a ketone group at the β position of the aliphatic side chain. Instead, it exhibits more similarities to substituted amphetamines.
  • Is 5-MMPA legal?
  • The legality of 5-MMPA can vary by country and region. It’s crucial to check your area’s specific laws and regulations, as designer drugs often face changing legal statuses.
  • What are the effects of 5-MMPA?
  • While the effects of 5-MMPA may vary from person to person, it is primarily a stimulant. Users might experience increased alertness, energy, and euphoria. However, as with any unregulated substance, its safety and side effects are not well-documented.
  • Is 5-MMPA safe to use?
  • The safety of 5-MMPA needs to be better researched, and its risks remain largely unknown. Since it is marketed as a designer drug, it needs more rigorous testing and regulation applied to pharmaceuticals. Consequently, using 5-MMPA can be risky.
  • How is 5-MMPA typically consumed?
  • Designer drugs like 5-MMPA are usually ingested, although routes of administration may vary. Some individuals can consume it orally, inhale, or even inject it.
  • What are the potential risks and side effects of 5-MMPA?
  • Due to the limited research on 5-MMPA, its risks and side effects are poorly understood. However, as with most stimulants, potential adverse effects may include increased heart rate, anxiety, paranoia, and addiction.
  • Is 5-MMPA addictive?
  • The addictive potential of 5-MMPA is uncertain. However, many stimulants can be habit-forming, leading to psychological and physical dependency in some users.
  • Can 5-MMPA be used for any legitimate medical purposes?
  • There is no known legitimate medical use for 5-MMPA. It is primarily marketed and consumed as a designer drug.
  • Where can I find more information about 5-MMPA?
  • To access up-to-date and reliable information about 5-MMPA, it’s best to consult scientific literature, forensic reports, or relevant government agencies that track emerging designer drugs and their effects. Always stay informed about the legal status of substances in your jurisdiction.

References

  1. EU Early Warning System Situation Report (EMCDDA – Situation Report 2, August 10, 2020)The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) published a situation report on August 10, 2020, as part of the EU Early Warning System. This report provides an overview of the evolving situation concerning new psychoactive substances (NPS) in Europe. NPS are substances designed to mimic the effects of controlled drugs, and they often pose unforeseen risks to public health.
  2. “Info” from www.aekwien.at (May 13, 2021)Additional information on this topic is available in a document titled “Info,” retrieved from www.aekwien.at on May 13, 2021. “Info” likely contains specific details or insights related to NPS and related issues, contributing to a broader understanding of the subject.
  3. New Psychoactive Substances: Global Markets, Glocal Threats, and the COVID-19 Pandemic (December 2020)In December 2020, the European Monitoring Center for Drugs and Drug Addiction (EMCDDA) released a comprehensive report titled “New Psychoactive Substances: Global Markets, Glocal Threats, and the COVID-19 Pandemic.” This report delves into the global markets of NPS and their impact on local and global threats. Furthermore, it explores the intricate interplay between the NPS market and the challenges posed by the COVID-19 pandemic, offering valuable insights into this complex issue.

Leave a Comment

Your email address will not be published. Required fields are marked *